DSIP
A neuromodulatory nonapeptide that promotes physiologic delta-wave sleep patterns and modulates stress-related endocrine function.
Also known as: Delta Sleep-Inducing Peptide, Delta sleep peptide, DSIP nonapeptide
Regulatory Status
Classification date: 2026-02-27
Reclassification to Category 1 announced but not yet formalized
Compounding: Not currently available for compounding
Evidence Summary
How It Works
DSIP is a nine-amino-acid peptide originally isolated from the blood of rabbits in electrically induced sleep states. It modulates GABAergic and glutamatergic neurotransmission, promotes delta-wave (slow-wave) sleep without suppressing REM, and influences the HPA axis by reducing ACTH and cortisol release under stress. It has also demonstrated analgesic properties and the ability to normalize disrupted circadian rhythms. Unlike sedative-hypnotics, it appears to restore physiologic sleep architecture rather than force sedation.
Common Applications
Safety & Considerations
No significant adverse effects reported in clinical studies. Does not produce morning grogginess, dependence, or rebound insomnia. Available data is predominantly from European studies in the 1980s-1990s. Limited modern clinical trial data. May interact with other sedatives or sleep medications. Currently not legal for compounding in the US.
Related Research
Regulatory classifications can change rapidly. The information shown here was last verified on 2026-02-27. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.